Derivatives and methods of treating hepatitis b infections

A compound of Formula I

• or a pharmaceutically acceptable salt thereof,
• wherein
• W1 and W are each independently selected from N, NRa, and CRa, wherein one of W1 and W is NRa;
• X is N or CRb;
• Y is selected from a bond, —C(O)—, and —SO2—;
• Z is selected from —(CR5R6)m—, —(CR5R6)mO—, —(CR5R6)mCR5═CR5—, —(CR5R6)m-C3-C6- cycloalkylene, and —(CR5R6)m—NR7—;
• R1 is selected from C(O)ORc, C(O)Rc, C(O)NRdRec, NRdC(O)Rc, —OC(O)Rc, —C(O)NRdORe;
• and —C(O)NRdN(Rd)2;
• R2 is, at each occurrence, independently selected from H, —OH, halo, C1-C6-alkyl, C1-C6-haloalkyl, —O-C1-C6-alkyl, and C1-C6-alkyl-OH;
• R3 is, at each occurrence, independently selected from H, —OH, halo, C1-C6-alkyl, C1-C6-haloalkyl, —O-C1-C6-alkyl, and C1-C6-alkyl-OH;
• R4 is selected from C1-C6-alkyl, —(CR8R9)p-C3-C8-cycloalkyl, —(CR8R9)p-C2-C8-heterocyclyl, (CR8R9)p-C6-C12-aryl, and —(CR8R9)p-C1-C9-heteroaryl, wherein alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl are optionally substituted with 1, 2, 3, or 4 groups, each independently selected from —OH, halo, CN, C1-C6-alkyl, C1-C6-haloalkyl, —O-C1-C6-alkyl, C(O)N(Rf)2, C(O)ORf, —OCH2C(O)ORf, —SO2Rf, and C1-C6-alkyl-OH;
• R5 is, at each occurrence, independently selected from H, —OH, halo, C1-C6-alkyl, C1-C6-haloalkyl, —O-C1-C6-alkyl, and C1-C6-alkyl-OH;
• alternatively, R4 and R5 are optionally joined to form a heterocyclic ring;
• R6 is, at each occurrence, independently selected from H, —OH, halo, C1-C6-alkyl, C1-C6-haloalkyl, —O-C1-C6-alkyl, and C1-C6-alkyl-OH;
• R7 is selected from H, C1-C6-alkyl, and C1-C6-alkyl-OH;
• R8 is, at each occurrence, independently selected from H, —OH, halo, C1-C6-alkyl, C1-C6-haloalkyl, —O-C1-C6-alkyl, and C1-C6-alkyl-OH;
• R9 is, at each occurrence, independently selected from H, —OH, halo, C1-C6-alkyl, C1-C6-haloalkyl, —O-C1-C6-alkyl, and C1-C6-alkyl-OH;
• Ra is selected from H, C1-C6-alkyl, and C1-C6-alkyl-OH;
• Rb is selected from H and C1-C6-alkyl;
• Rc is selected from H, C1-C6-alkyl, C1-C6-alkyl-OH, C1-C6-alkyl-C3-C8-cycloalkyl, C2-C8-heterocyclyl, C6-C12-aryl, and C1-C9-heteroaryl, wherein cycloalkyl, heterocyclyl, aryl, and heteroaryl are optionally substituted with 1, 2, or 3 groups, each independently selected from —OH, halo, CN, C1-C6-haloalkyl, and —O-C1-C6-alkyl;
• Rd is selected from H, C1-C6-alkyl, and C1-C6-alkyl-OH;
• Re is selected from H, C1-C6-alkyl, C1-C6-alkyl-OH, C1-C6-alkyl-C1-C6-alkyl, C0-C6-alkyl-C3-C8-cycloalkyl, C2-C8-heterocyclyl, C6-C12-aryl, and C1-C9-heteroaryl, wherein cycloalkyl, heterocyclyl, aryl, and heteroaryl are optionally substituted with 1, 2, or 3 groups, each independently selected from —OH, halo, CN, C1-C6-alkyl, C1-C6-haloalkyl, and —O-C1-C6-alkyl;
• alternatively, Rd and Re are optionally joined to form a heterocyclic ring, which is optionally substituted with 1, 2, or 3 groups, each independently selected from —OH, halo, CN, C1-C6-haloalkyl, and —O-C1-C6-alkyl;
• Rf is, at each occurrence, independently selected from H and C1-C6-alkyl;
• m is C, 1, 2, 3, or 4;
• n is C, 1, 2, or 3;
• and
• p is C, 1, 2, 3, or 4.